Researchers evaluated factors contributing to surgical attrition in non-metastatic pancreatic cancer. Clinical trials showed 25-30% of patients did not undergo surgery, mainly due to disease progression. The overall surgical rate in the national cancer database was 49%, increasing to 67% in a cohort resembling clinical trial patients. Low-volume institutions and uninsured or Medicaid-insured patients were less likely to receive potentially curative surgery. A realistic target surgery rate of 70-75% in potentially-resectable pancreatic cancer was identified, highlighting the impact of non-medical barriers such as facility volume and insurance.
Journal Article by Kakish H, Zhao J (…) Hoehn RS et 6 al. in HPB (Oxford)
Copyright © 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.